Innovation consortium Longitude Health’s board of managers approved funding for two new utilities: Longitude Clinical Trial Services and Longitude Cell and Gene Therapy.
The additions bring Longitude Health’s utility count to four, joining Longitude Rx, launched in December 2024, and Longitude Fx, approved in April, according to a July 21 news release.
Longitude Health was launched in October 2024 by four major nonprofit health systems: Renton, Wash.-based Providence; Dallas-based Baylor Scott & White Health; Houston-based Memorial Hermann Health System; and Winston-Salem, N.C.-based Novant Health. Longitude was formed with the aim of tackling “the most impactful challenges and opportunities in the healthcare industry.” Ann Arbor-based Michigan Medicine joined as a member in May 2025.
Longitude CTS aims to expand health system participation in clinical research by broadening patient access and diversifying revenue, according to the release. Thad Wolfram was named CEO of Longitude CTS. He previously served as chief strategy officer at PCM and president of EmVenio Research.
Longitude CGT will serve as a subsidiary of Longitude Rx, according to the release. It will initially partner with Michigan Medicine and Providence to address the operational and reimbursement complexity of advanced therapies. Sinthu Sinnadurai was named president of Longitude CGT. Mr. Sinnadurai previously served as vice president at Cambridge, Mass.-based Beth Israel Lahey Health and director of pharmacy business operations at Palo Alto, Calif.-based Stanford Health Care.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.